1. Home
  2. BAFN vs RGNT Comparison

BAFN vs RGNT Comparison

Compare BAFN & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$5.78

Market Cap

26.6M

Sector

Finance

ML Signal

N/A

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$2.00

Market Cap

24.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAFN
RGNT
Founded
1999
2004
Country
United States
Israel
Employees
N/A
8
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
24.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BAFN
RGNT
Price
$5.78
$2.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.9K
677.4K
Earning Date
04-30-2026
05-05-2026
Dividend Yield
1.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.26
$1.23
52 Week High
$15.28
$15.50

Technical Indicators

Market Signals
Indicator
BAFN
RGNT
Relative Strength Index (RSI) 55.97 39.53
Support Level $4.80 $1.82
Resistance Level $5.90 $3.35
Average True Range (ATR) 0.35 0.47
MACD 0.09 -0.26
Stochastic Oscillator 81.82 0.19

Price Performance

Historical Comparison
BAFN
RGNT

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Share on Social Networks: